On July 2, Abivax S.A. rose 5.39% in regular trading, trading at approximately $140.64 per share, with turnover of $67.40 million.

On the news front, the company announced that underwriters of its American depositary share public offering have fully exercised their option to purchase an additional 960,000 ADSs, increasing gross proceeds from $800 million to approximately $920 million. The offering is expected to close on Monday, subject to customary closing conditions. Net proceeds of approximately $874.1 million will be used to support the potential U.S. commercialization of obefazimod, clinical research on ulcerative colitis and Crohn's disease, and general corporate purposes.

The offering was initially launched at $600 million before being upsized to $800 million at a price of $125 per ADS, reflecting strong institutional demand. The full exercise of the overallotment option further reinforces market confidence, particularly following positive Phase 3 ABTECT maintenance trial data that dispelled prior safety concerns related to malignancy cases in the 50 mg cohort, which had previously driven the stock from $130 to approximately $70. The current share price continues to trade well above the $125 offering price.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)